Nuplazid Side Effects

The drug Nuplazid has recently been linked to serious health issues and even death, among other side effects. If you or a loved one have experienced complications after being treated with Nuplazid, you may be entitled to compensation for medical bills, lost income and pain and suffering, among other losses. We are currently working with experienced Nuplazid lawyers across the country. They charge no fee unless you get an award or settlement. For a free (no obligation) case evaluation, call our toll free number 24/7 or fill out a contact form online.

Have You Suffered Any Serious Side Effects Due to Nuplazid?
Call Us Today!

What Is Nuplazid?

Nuplazid PillsNuplazid (generic name Pimavanserin) is a new drug manufactured by Acadia Pharmaceuticals and intended to treat psychosis symptoms in patients suffering from Parkinson’s disease and Alzheimer’s disease. The drug is primarily prescribed to patients suffering with symptoms including hallucinations, changes in personality, and severe mood swings that are generally associated with the progression of Parkinson’s and Alzheimer’s. It has been called a “scientific breakthrough” as the first drug to treat these symptoms in Parkinson’s patients. With about one million people in the U.S. suffering from the effects of Parkinson’s, and about half of those individuals experiencing psychosis, the drug has been a welcome and popular treatment choice. However, many adverse side effects, and even a large number of deaths have been reported in connection with the drug, leaving many questioning its safety.

Why is Nuplazid Dangerous?

Nuplazid blocking signnals in the BrainNuplazid hit the market in June of 2016 promising to ease the symptoms experienced by patients suffering from Parkinson’s and Alzheimer’s. The medication works differently than most antipsychotic drugs by blocking certain signals in the brain that control memory, cognition, learning, movement, and other body functions. It is thought that this new approach can lead to a substantial risks, especially in elderly patients, patients with heart problems, and patients who take other antipsychotic drugs.

A recent report published by Quarter Watch in November of 2017 indicates that the risks associated with Nuplazid may outweigh any benefit the medication provides. The drug was approved by the FDA using a “fast track” method utilizing limited scientific data. In fact, there was only one clinical trial involving just under 200 patients conducted to evaluate the safety and effectiveness of the drug. One medical reviewer indicated that the drug should not have been approved because it displayed only minimal effectiveness but doubled the risk of death and other serious adverse effects in patients.

After being treated with Nuplazid, a large number of patients, family members, and health care providers began to report disturbing and dangerous adverse events that may be associated with the medication. In over 1,000 reports, patients continued to experience hallucinations. Many patients reported the hallucinations actually getting worse and more intense. Other reports have included falls, insomnia, nausea, fatigue, and even death after starting the medication. More than 700 deaths have been reported in connection with Nuplazid.

What Are Some Other Nuplazid Side Effects

Increased Hallucinations and Confusion from NuplazidAccording to the FDA, the most common side effects of Nuplazid include swelling of the ankles, legs, and feet due to fluid retention (peripheral edema); nausea; and changes in mental state or confusion. Many patients and care givers report that the drug actually increases hallucinations and confusion. Others report that the drug is completely ineffective and does not help reduce psychosis symptoms. Unfortunately, a growing number of deaths continue to be reported in connection with Nuplazid, which has many questioning if the benefits of the drug outweigh the risks it poses to already vulnerable patients.

Fast Track FDA Approval for Nuplazid

Nuplazid was granted FDA approval in April of 2016 under a fast track approval process known as Breakthrough Therapy. The process is designed to speed up the approval process for new medications that are intended to treat serious conditions where preliminary clinical data shows a clear advantage over other currently available treatment options. Under this designation, drugs may gain approval with minimal scientific data. In the case of Nuplazid, the designation was quickly granted as the drug is the first of its kind to treat psychosis in Parkinson’s patients the way it does. However, the data collected indicates that Nuplazid was only minimally effective and had the potential to increase the risk of death, especially in elderly patients.

What Is The FDA Doing About Nuplazid?

The FDA testing Nuplazid

The Food and Drug Administration (FDA) required Arcadia to place a box warning on the label of Nuplazid warning of the increased risk of death associated with taking the medication. The FDA also indicated in an email to Parkinson’s News Today, that it would be closely monitoring the safety of Nuplazid in the wake of the high number of adverse events reported. There are no indications that further actions will be taken against Arcadia to protect patients from this potentially dangerous medication.

Are There Nuplazid Lawsuits?

Nuplazid LawsuitsDue to the large number of adverse events, side effects, and deaths reported in connection with Nuplazid, injured patients and families across the county have been filing lawsuits against the makers of the drug. While these suits are still in the beginning stages, many law firms have been taking these cases and investigating the dangers associated with Nuplazid.

Contact an Experienced Nuplazid Lawyer Today!

Nuplazid LawyerIf you or a loved one have suffered from serious side effects after being treated with Nuplazid, you may be entitled to compensation for medical expenses, lost income and pain and suffering, among other losses. We are working with experienced Nuplazid lawyers across the country that handle these cases. There is no legal fee unless you receive a settlement or award. For a free (no obligation) case evaluation, call our toll free number anytime at 1-800-992-6878 or fill out a contact form online.

Sources:

  1. https://www.ismp.org/quarterwatch
  2. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm498442.htm
  3. https://parkinsonsnewstoday.com/2018/04/16/fda-says-monitoring-nuplazid-in-parkinsons-patients-but-sees-no-shift-from-expected
  4. https://www.cnn.com/2018/04/09/health/parkinsons-drug-nuplazid-invs/index.html